Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-28T02:58:10.039Z Has data issue: false hasContentIssue false
  • English
  • Français

Basic concepts and new aspects of vaccine development

Published online by Cambridge University Press:  06 April 2009

I. M. Roitt
I. M. Roitt
Affiliation:
Department of Immunology, University College and Middlesex School of Medicine, London WI
Get access Rights & Permissions [Opens in a new window]

Abstract

I wish to thank the Society for inviting me to give the Introductory Talk in this Symposium. It is going to centre around what might be called ‘epitope specific’ immunization and I want to draw your attention to a number of factors which will be bound to affect any new approach to the development of vaccines. To begin with, it is now clear that complex antigens, such as those associated with parasites, present many different epitopes to the immune system. These epitopes are ‘seen’ by different cell types using different receptors and epitope recognition can activate a number of different effector systems.

Keywords

vaccine developmentepitope recognitionprotein engineeringB cell responsesT cell responses.
Type
Research Article
Information
Parasitology , Volume 98 , supplement S1: Symposia of the British Society for Parasitology Volume 26:Vaccines and vaccination strategies , January 1989 , pp. S7 - S18
Copyright
Copyright © Cambridge University Press 1989

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Bittle, J. L., Houghton, R. A., Alexander, H., Shinnick, T. M., Sutcliffe, J. G., Lerner, R. A., Rowlands, D. J. & Brown, F. (1982). Protection against foot-and-mouth disease by immunization with a chemically synthesised peptide predicted from the viral nucleotide sequence. Nature, London 298, 30–3.CrossRefGoogle ScholarPubMed
commission of the ec-ad hoc working party on biotechnology and pharmacy (1987). Guidelines on the production and quality control of medicinal products derived by rDNA technology. Trends in Biotechnology 5.Google Scholar
Mackett, M., Smith, G. L. & Moss, B. (1982). Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proceedings of the National Academy of Sciences, USA 79, 7415–19.Google Scholar
Miyanohara, A., Toh-e, A., Nozaki, C., Hamada, F., Ohtomo, N. & Matsubara, K. (1983). Expression of hepatitis B surface antigen in yeast. Proceedings of the National Academy of Sciences, USA 80, 1–5.CrossRefGoogle ScholarPubMed
Newtown, S. E., Clarke, B. E., Appleyard, G., Francis, M. J., Carroll, A. R., Rowlands, D. J., Skehel, J. & Brown, F. (1987). New approaches to FMDV antigen presentation using vaccinia virus. In Vaccines 87: Modern Approaches to New Vaccines (ed. Chanock, R. M., Lerner, R. A., Brown, F. and Ginsberg, H.), pp. 12–21. New York: Cold Spring Harbor Laboratory.Google Scholar
Panicali, D. & Paoletti, E. (1982). Construction of poxviruses as cloning vectors: insertion of thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proceedings of the National Academy of Sciences, USA 79, 4927–31.CrossRefGoogle ScholarPubMed
Smith, G. E., Ju, G., Ericson, B. I., Moschera, J., Lahm, H. W., Chizzonite, R. & Summers, M. D. (1985). Modification and secretion of human interleukin-2 produced in insect cells by baculovirus expression vector. Proceedings of the National Academy of Sciences, USA 82, 8404–48.Google Scholar
Stanway, G., Hughes, P. J., Mountford, R. C., Reeve, P., Minor, P. D., Schild, G. C. & Almond, J. W. (1984). Comparison of the complete nucleotide sequences of the genomes of the neurovirulent polioviruses P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a, b. Proceedings of the National Academy of Sciences, USA 81, 1539–43.CrossRefGoogle Scholar
Valenzuela, P., Medina, A., Rutter, W. J., Ammerer, G. & Hali, B. D. (1983). Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature, London 298, 347–50.CrossRefGoogle Scholar